NCT05358691 2025-04-16A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC ParticipantsRutgers, The State University of New JerseyPhase 1 Withdrawn
NCT05383001 2022-09-27Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)AIO-Studien-gGmbHPhase 2 Withdrawn